The Fund does not foresee any future calls
The University of Lausanne (UNIL) and the École Polytechnique Fédérale de Lausanne (EPFL) are pleased to announce a call for proposals to award one exceptional collaborative project in the field of genomic, precision medicine, cancer or translation neurosciences.
This award is made possible thanks to a donation from the Société Académique Vaudoise supported by the Novartis Consumer Health Foundation for the advancement of the biological, medical and pharmaceutical sciences.
- Deadline: 31 October 2018.
- Awards will be made public by end of December 2018.
- Earliest start of the project: February – April 1, 2019.
- This call is dedicated to applied research proposals in the general areas of genomic, precision medicine, cancer or translational neurosciences.
- Proposals must be collaborative: one principal investigator at UNIL and one principal investigator at EPFL.
- Established senior scientists from UNIL and EPFL are invited to apply: full professors, associate professors, PATT (EPFL), PAST and PAST PTC (UNIL), adjunct professors, MER, SNSF-funded professors and senior scientists. The host institutions must employ the PI for the entire duration of the project.
For further information and links to the application package, please have a look at the application guidelines.
- Research proposals should be in the topic of genomic, precision medicine, cancer or translational neurosciences.
- Scientific excellence of the research proposal.
- Originality/Innovative nature of the project (in relation to the relevant state-of-the-art).
- Excellence of the applicants.
- Impact of the proposal on the relevant scientific field and on the long-term collaboration between a research group at UNIL and at EPFL.
- Preference will be given to new projects. Proposals to continue ongoing work in a laboratory will be less favorably reviewed.
For more information on the evaluation criteria and the evaluation committee, please have a look at the call guidelines.
Capturing the functional heterogeneity of tumor-specific CD4 T cells in real-time using nanoplasmonic biosensors for T-cell based immunotherapy – Prof. Hatice Altug (EPFL), Dr. Camilla Jandus (UNIL).